Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.  CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024.  Century Therapeutics plans to pursue additional autoimmune disease indication regulatory filings in 2024.  The company announced a $60 million private placement to support Century Therapeutics’ increased R&D activities in autoimmune diseases.  Century will issue approximately 15.87 million shares at $3.78. The company estimates that its cash, cash equivalents, and investments will support operations into 2026. Concurrently, Century announced pipeline and ...